JP2003508079A - 老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長 - Google Patents

老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長

Info

Publication number
JP2003508079A
JP2003508079A JP2001521771A JP2001521771A JP2003508079A JP 2003508079 A JP2003508079 A JP 2003508079A JP 2001521771 A JP2001521771 A JP 2001521771A JP 2001521771 A JP2001521771 A JP 2001521771A JP 2003508079 A JP2003508079 A JP 2003508079A
Authority
JP
Japan
Prior art keywords
cells
cell
gene
telomerase
cloned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001521771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508079A5 (enExample
Inventor
ウエスト、マイケル
ランザ、ロバート、エル
シベリ、ホセ
Original Assignee
アドバンスド セル テクノロジー、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド セル テクノロジー、インコーポレイテッド filed Critical アドバンスド セル テクノロジー、インコーポレイテッド
Publication of JP2003508079A publication Critical patent/JP2003508079A/ja
Publication of JP2003508079A5 publication Critical patent/JP2003508079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
JP2001521771A 1999-09-07 2000-09-06 老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長 Pending JP2003508079A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15234099P 1999-09-07 1999-09-07
US60/152,340 1999-09-07
US17948600P 2000-02-01 2000-02-01
US60/179,486 2000-02-01
US52702600A 2000-03-16 2000-03-16
US09/527,026 2000-03-16
US52087900A 2000-04-05 2000-04-05
US09/520,879 2000-04-05
PCT/US2000/024393 WO2001018236A1 (en) 1999-09-07 2000-09-06 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells

Publications (2)

Publication Number Publication Date
JP2003508079A true JP2003508079A (ja) 2003-03-04
JP2003508079A5 JP2003508079A5 (enExample) 2007-11-01

Family

ID=27496015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001521771A Pending JP2003508079A (ja) 1999-09-07 2000-09-06 老年期体細胞からクローン化された動物中の細胞寿命のテロメア回復と延長

Country Status (10)

Country Link
EP (1) EP1214443A4 (enExample)
JP (1) JP2003508079A (enExample)
CN (1) CN1377424A (enExample)
AU (1) AU7350800A (enExample)
BR (1) BR0013844A (enExample)
CA (1) CA2383790C (enExample)
IL (2) IL148457A0 (enExample)
MX (1) MXPA02002443A (enExample)
NZ (1) NZ531844A (enExample)
WO (1) WO2001018236A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012120486A (ja) * 2010-12-08 2012-06-28 Kinki Univ 免疫不全動物を用いた細胞の製法
JP2023099826A (ja) * 2013-03-15 2023-07-13 エリクサージェン セラピューティクス，インコーポレイティド ヒト細胞を若返らせるためのｚｓｃａｎ４の使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148418A0 (en) * 1999-09-07 2002-09-12 Advanced Cell Tech Inc Method for generating immune-compatible cells and tissues using nuclear transfer techniques
US7713728B2 (en) 2007-01-08 2010-05-11 The Invention Sciencefund I, Llc Systems for genome selection
US7947455B2 (en) 2007-01-08 2011-05-24 The Invention Science Fund I, Llc System for genome selection
US7985578B2 (en) 2007-01-08 2011-07-26 The Invention Science Fund I, Llc Systems for genome selection
US7718418B2 (en) 2007-01-08 2010-05-18 The Invention Science Fund I, Llc Systems for genome selection
US7709244B2 (en) 2007-01-08 2010-05-04 The Invention Science Fund I, Llc Systems for genome selection
US7648823B2 (en) 2007-01-08 2010-01-19 Searete Llc Systems for genome selection
US7888036B2 (en) 2007-01-08 2011-02-15 The Invention Science Fund I, Llc Systems for genome selection
US7947457B2 (en) 2007-01-08 2011-05-24 The Invention Science Fund I, Llc Systems for genome selection
US8521440B2 (en) 2007-01-08 2013-08-27 The Invention Science Fund I, Llc Systems for genome selection
US7709245B2 (en) 2007-01-08 2010-05-04 The Invention Science Fund I, Llc Systems for genome selection
US8012740B2 (en) 2007-01-08 2011-09-06 The Invention Science Fund I, Llc Systems for genome selection
US20110086424A1 (en) * 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
WO2012136841A1 (en) * 2011-04-08 2012-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for rejuvenating cells
EP3869195B1 (en) 2015-03-23 2024-03-20 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
AU2019333905B2 (en) * 2018-09-06 2025-12-11 The Board Of Regents Of The University Of Texas System Telomerase holoenzyme complex and methods of use thereof
EP4525895A4 (en) * 2022-05-17 2026-05-13 Nat Univ Singapore Somatic cell therapy to treat female infertility

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039416A1 (en) * 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
JP2003509028A (ja) * 1999-09-07 2003-03-11 アドバンスド セル テクノロジー、インコーポレイテッド 核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648215A (en) * 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
GB9809178D0 (en) * 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
WO2001000650A1 (en) * 1999-06-30 2001-01-04 Advanced Cell Technology, Inc. Cytoplasmic transfer to de-differentiate recipient cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039416A1 (en) * 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
JP2003509028A (ja) * 1999-09-07 2003-03-11 アドバンスド セル テクノロジー、インコーポレイテッド 核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012120486A (ja) * 2010-12-08 2012-06-28 Kinki Univ 免疫不全動物を用いた細胞の製法
JP2023099826A (ja) * 2013-03-15 2023-07-13 エリクサージェン セラピューティクス，インコーポレイティド ヒト細胞を若返らせるためのｚｓｃａｎ４の使用方法
JP7633309B2 (ja) 2013-03-15 2025-02-19 エリクサージェン セラピューティクス，インコーポレイティド ヒト細胞を若返らせるためのｚｓｃａｎ４の使用方法
JP2025065335A (ja) * 2013-03-15 2025-04-17 エリクサージェン セラピューティクス，インコーポレイティド ヒト細胞を若返らせるためのｚｓｃａｎ４の使用方法

Also Published As

Publication number Publication date
CN1377424A (zh) 2002-10-30
WO2001018236A1 (en) 2001-03-15
IL148457A (en) 2013-01-31
BR0013844A (pt) 2002-05-14
NZ531844A (en) 2005-08-26
AU7350800A (en) 2001-04-10
CA2383790C (en) 2016-11-22
MXPA02002443A (es) 2004-07-16
CA2383790A1 (en) 2001-03-15
IL148457A0 (en) 2002-09-12
EP1214443A4 (en) 2003-08-27
EP1214443A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
US20040180430A1 (en) Methods of restoring telomere length and extending cell lifespan using nuclear transfer
CA2383790C (en) Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
Sasaki et al. Epigenetic events in mammalian germ-cell development: reprogramming and beyond
WO2001018236A9 (en) Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
CA2377515C (en) Cytoplasmic transfer to de-differentiate recipient cells
Jaenisch et al. Nuclear cloning, epigenetic reprogramming, and cellular differentiation
US20040199935A1 (en) Cytoplasmic transfer to de-differentiate recipient cells
JP2004524832A (ja) 細胞の運命を変化させる方法
Pellegrini et al. Agenesis of the scapula in Emx2 homozygous mutants
AU759322B2 (en) Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
JP4223284B2 (ja) 予め選抜されたイムノタイプおよび／またはジェノタイプを有するホモ接合性幹細胞群の製造方法、該細胞由来の移植に適切な細胞、並びにこれらを用いた材料および方法
JP2003514516A (ja) 多能性細胞と細胞株の雌性発生的または雄性発生的産生および分化した細胞と組織を産生するためのその使用
JP2002537785A (ja) 体細胞の遺伝的改変とそれらの使用
JP2002537803A (ja) 異種間核移植により産生される胚性細胞株あるいは幹様細胞株
JP2002512787A (ja) 幹細胞を得る方法
JP2004500066A (ja) 異種間核移植により生成する胚あるいは幹様細胞
JP2003514515A (ja) 核移行のためのドナー細胞の調製と選択
US20040040050A1 (en) Production of agricultural animals from embryonic stem (es) cells
JP2000505294A (ja) 分化の阻害のためのｄｉａ／ｌｉｆ―欠損胚幹細胞により発現されるサイトカイン
US20120196769A1 (en) Methods of repairing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
JP2006522609A (ja) 動物の体細胞核移植と関係する紡錘体欠損を修正するための方法
AU2006252076A1 (en) Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
Zhang et al. Deletion of RBM20 exon 9 impairs skeletal muscle growth and satellite cell function in pigs
JP2003509028A (ja) 核移植技術を用いた免疫適合性を有する細胞及び組織を産生する方法
Camp The Known MyoD Enhancers are Largely Dispensable for Proper Embryonic Expression and Cells of the MyoD Expressing Lineage are Multipotent in the Trunk but Not the Limbs of Amyogenic Embryos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110415